Diabetes and Vascular Disease Research

Aims & Scope

Diabetes & Vascular Disease Research is the first international peer-reviewed journal to unite diabetes and vascular disease in a single title.

Diabetes & Vascular Disease Research is an open access journal.

It mirrors the increasing recognition that diabetes and cardiovascular disease are a single entity in which diabetes and related disorders, such as insulin resistance, are directly linked with assaults on the vessel wall and the development of vascular risk clustering.

Diabetes & Vascular Disease Research: Links diabetes, its metabolic consequences and vascular outcomes Original research in fields of insulin resistance and metabolic disorders Promotes understanding of pathology, aetiology and management of thrombosis, hyperglycaemia, hypertension, dyslipidaemia and micro- and macrovascular consequences.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science
• Embase

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 2,100.00 USD. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences

  Citation: 332

  Authors: Linda A, Ernest M, Volker

• SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

  Citation: 322

  Authors: Silvio E, Bernard, Christoph, Roberto, David, Stefan, Rosa-Maria, Hans-Jürgen, Uli C, Odd Erik

• Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome

  Citation: 242

  Authors: Timo, Markku, Jaana, Liisa, Jouko, Johan Gunnar, Jaakko

• Metformin therapy and clinical uses

  Citation: 228

  Authors: John HB, Harry CS

• Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift

  Citation: 221

  Authors: Christopher J, Marc

• Homocysteine and cardiovascular disease: a review of the evidence

  Citation: 210

  Authors: Anthony S

• Metabolic syndrome, or What you will: definitions and epidemiology

  Citation: 206

  Authors: Caroline

• The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

  Citation: 206

  Authors: Jean-Charles, Frank M, Michel P, Gerd, W Virgil, Richard, M John, Paul M, Paola, Henry N, Takashi, Jean-Marc, Nikolaus, Jorge, Zeljko, Robert S, Bart, Jane K, Rody, Christoph, Alberto, Paul

• The endothelium and vascular inflammation in diabetes

  Citation: 199

  Authors: Martin M, Thomas, Ulrich

• Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature

  Citation: 186

  Authors: Sopida